Zingerone

Zingerone (Vanillylacetone): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Natural Source

1.1 Nomenclature and Chemical Identity

Zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone) is a nontoxic and inexpensive compound with varied pharmacological activities. It is also known by the synonyms gingerone, vanillylacetone, and 4-(3-methoxy-4-hydroxyphenyl)-butan-2-one, with the molecular formula C₁₁H₁₄O₃. Its CAS registry number is 122-48-5. Zingerone, also called vanillylacetone, is a major flavor component of ginger, providing the sweet flavor of cooked ginger. It is a crystalline solid that is sparingly soluble in water and soluble in ether.

Zingerone is similar in chemical structure to other flavor chemicals such as vanillin and eugenol. Zingerone is closely related to vanillin from vanilla and eugenol from clove. Structurally, it is classified as a phenolic alkanone (also described as a methoxyphenol), characterized by a guaiacol (2-methoxyphenol) moiety attached to a butanone side chain. It contains a methoxy phenol group, which consists of a basic phenolic ring with a methoxy group attached to a benzene ring.

1.2 Natural Source and Botanical Origin

Zingerone is a flavor phytochemical present in ginger, a flowering plant belonging to the Zingiberaceae family used as a condiment and herbal remedy. Ginger (Zingiber officinale Roscoe, family: Zingiberaceae) originated in South-East Asia and is the most common spice used all over the world. It is a pungent, aromatic spice which adds a special flavor and zest to food. Ginger is the underground rhizome of the ginger plant. This perennial herb is largely grown as both a spice and a condiment.

Critically, zingerone is not a primary constituent of fresh ginger root. Fresh ginger does not contain zingerone, but it is produced by cooking or drying of the ginger root, which causes a reverse aldol reaction on gingerol. Through a retro aldol reaction, the alkyl chain is cleaved and results in the formation of zingerone (4-(4-hydroxy-3-methoxyphenyl)butan-2-one), C₁₁H₁₄O₃. As a result, zingerone concentration in dried ginger is present in a greater amount. Zingerone is produced from gingerols during drying, having lower pungency and a spicy-sweet aroma. Shogaols are more pungent and are formed from gingerols during heating, storage, or via acidity.

1.3 Discovery and Synthesis

Zingerone was first isolated from the ginger root in 1917 by Hiroshi Nomura, a chemistry professor at Tokyo Imperial University. Nomura named the compound and identified the empirical formula of zingerone in his studies at the laboratory of the Agricultural College. He initially identified it as the chemical component contributing pungency to ginger, something further work has disproven. Nomura identified and later patented a method for the synthesis of zingerone, in which vanillin and acetone are reacted under basic conditions (via an Aldol condensation) to form dehydrozingerone. Only in the past century has zingerone been produced synthetically.

1.4 Pungency Profile and Role in Ginger

Zingerone is the least pungent component of Zingiber officinale. Zingerone, usually formed during the processing or cooking of ginger, has a sweeter, more aromatic scent and is far less pungent than its precursor, gingerol. More than 60 active constituents are known to be present in ginger, which have been broadly divided into volatile and non-volatile compounds. Hydrocarbons, mostly monoterpenoid hydrocarbons and sesquiterpenes, include the volatile component of ginger and impart a distinct aroma and taste to ginger. Nonvolatile compounds include gingerols, shogaols, paradols, and also zingerone.

1.5 Common Forms and Preparations

Zingerone is encountered in several forms and contexts:

• Dried and cooked ginger: Zingerone is absent in fresh ginger but cooking or heating transforms gingerol to zingerone. It is therefore naturally present in dried ginger powder, ginger ale, ginger beer, ginger-based baked goods, and preserved gingers.
• Isolated/synthesized compound: It is used as a flavor additive in spice oils and in perfumery to introduce spicy aromas.
• Food flavoring (GRAS): The US FDA has affirmed that Zingiber officinale is generally recognized as safe (GRAS) as a spice, natural seasoning agent, and flavoring agent [21CFR182.10]. Zingerone itself is listed with the Flavor and Extracts Manufacturers Association (FEMA) and has been reviewed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Safety evaluation of certain food additives and contaminants was prepared by the fifty-fifth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), published in WHO Food Additives Series No. 46, 2001.
• Research compound: Zingerone is commercially available as a pure chemical (CAS 122-48-5) for laboratory and preclinical research.

2. Traditional and Historical Use

2.1 Ancient and Cross-Cultural Use of Ginger as the Vehicle for Zingerone

The history of zingerone as an isolated molecule is modern — its first isolation dates only to 1917. However, zingerone is intrinsically produced whenever ginger is dried, cooked, or processed, meaning populations using dried or cooked ginger throughout history were consuming zingerone as part of the preparation. The historical record is therefore that of Zingiber officinale in its heated or dried preparations.

Ginger has a long history of medicinal use dating back 2500 years. Ginger has been traditionally used from time immemorial for varied human ailments in different parts of the globe, to aid digestion and treat stomach upset, diarrhoea, and nausea. Ginger (Zingiber officinale Roscoe, Zingiberaceae) is a medicinal plant that has been widely used in Chinese, Ayurvedic, and Tibb-Unani herbal medicines all over the world, since antiquity, for a wide array of unrelated ailments that include arthritis, rheumatism, sprains, muscular aches, pains, sore throats, cramps, constipation, indigestion, vomiting, hypertension, dementia, fever, infectious diseases, and helminthiasis.

2.2 Chinese Medicine

Ginger (Zingiber officinale) has been used as a spice and medicine for over 200 years in Traditional Chinese Medicine. Chinese herbals like the Shen Nong Ben Cao Jing (circa 1st century CE) described "Sheng Jiang" for its digestive and warming functions. Chinese medical texts from the fourth century BCE suggest that ginger was used for treating nausea, diarrhea, stomachache, cholera, toothaches, bleeding, and rheumatism.

2.3 Ayurvedic Medicine (India)

Traditionally, Ayurveda uses the dried rhizome (Shunti) and fresh rhizome (Ardraka) separately: fresh for digestive upsets, dried for longer shelf life and warming action. Because zingerone forms preferentially in dried preparations, dried ginger (Shunti) is the Ayurvedic form most likely to deliver significant zingerone content. Ayurveda's Charaka Samhita (~2nd century CE) called Shunti a remedy for "ama" (toxins) and Vata imbalances. Ginger is used in Ayurvedic medicine for the treatment of different ailments, including headache, pain, respiratory diseases, indigestion, fever, common cold and cough.

2.4 Iranian Traditional Medicine

Zingiber officinale, named "zangabil" in Persian, belonging to the Zingiberaceae family, has been used alone or in compounds as a spice or remedy in ancient recipes of Iranian Traditional Medicine (ITM) manuscripts. This plant is endemic to India and cultivated in South and South-East Asia, Africa, Latin America, and Australia. Some of the important applications of ginger in ITM manuscripts are as follows: a tonic for the memory and digestive system, the hepatic obstructions opener, aphrodisiac, for expelling compact wind from stomach and intestine, diluting, desiccating, and emollient of phlegmatic and compact humor sticking to stomach, intestine, brain, and throat.

2.5 Global Spread and Other Traditions

Ginger first appeared in the writings of Confucius in the 5th century BC, and it has been used medicinally in the West for the past 2000 years. Henry VIII recommended it as a prophylactic against the plague. It was introduced by the Spaniards to the Americas and is now cultivated extensively in the West Indies. The Portuguese introduced it to West Africa. Ginger is also used in traditional oriental medicine (Ayurvedic, Chinese, and Unani systems of medicine) since antiquity (>2500 years) to treat different diseases that include rheumatoid arthritis, sprains and muscular aches, sore throats, nausea, constipation and indigestion, fever, infectious diseases, and helminthiasis.

3. Key Active Constituents and Phytochemical Context

Active compounds credibly linked to Zingiber officinale include gingerol, shogaol, and zingerone, along with smaller amounts of paradol, beta-sesquiphellandrene, and zingiberene. The major players are gingerols — especially [6]-gingerol — which transform into shogaols (notably [6]-shogaol) when heated or dried. Zingerone is produced by a distinct process: zingerone, formed when gingerols undergo heat-induced breakdown, contributes antioxidant capacity, scavenging free radicals in vitro.

Zingerone belongs to the phenolic alkanone subclass of phytochemicals. Its defining structural feature — the methoxy-hydroxyphenyl group — is shared with vanillin and eugenol, explaining structural analogies in flavor and some biological activities. The butanone (ketone) side chain distinguishes it chemically from shogaols (which carry an α,β-unsaturated carbonyl) and accounts for its markedly reduced pungency compared to gingerols and shogaols.

4. Mechanisms of Action

4.1 Antioxidant Mechanisms

The first evidence suggestive of antioxidant properties exhibited by zingerone is that zingerone has the ability to degrade free radicals generated by radiolysis of various food products. The observation that zingerone minimizes oxidation of lipids undoubtedly signifies its role as an antioxidant. Zingerone proved to be a highly efficient free radical scavenger by inhibiting enzymes involved in the formation of reactive oxygen and nitrogen species (RONS).

The prevention of oxidative stress and ROS formation capability of zingerone may be due to the following biochemical mechanism: the methoxyl group generally succors the release of a proton from the hydroxyl group. Zingerone aids in increasing the bulk, stabilization, and partition coefficient by the presence of the long-chain ethyl methyl ketone group in its structure. This property of zingerone could help penetrate into cells and quench free radicals.

Zingerone lessens oxidative stress, inflammation, apoptosis, and oxidative DNA damage by increasing the activities of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and glutathione peroxidase (GPX).

4.2 Anti-inflammatory Mechanisms

The anti-inflammatory actions of zingerone are mediated through multiple intracellular pathways. The mechanism of action of zingerone may be related to significant inhibition of the mRNA expression of inflammatory markers (TLR4, RelA, NF-κB2, TNF-α, iNOS, COX-2), indicating that zingerone interferes with cell signalling pathways and suppresses hyper-expression of cell signaling molecules of the inflammatory pathway.

In recent studies, the molecular mechanism of zingerone treatment on pro-inflammatory NF-κB activation via the redox-related NIK/IKK and MAPK pathways was examined. The action mechanism of zingerone on NF-κB signaling was investigated in aged rat kidney and endothelial cells. The results showed that zingerone had not only the antioxidant effect by constitutive suppression of ROS, but also anti-inflammatory effects by suppression of NF-κB activation in aged rat.

Zingerone prevents alginate production, which increases the cell's susceptibility to macrophages, serum, and antibiotics, and dramatically lowers the generation of proinflammatory cytokines brought on by lipopolysaccharide (LPS). Cytokine production, MAPK, and NF-κB activation are all inhibited dose-dependently by zingerone.

Zingerone attenuated nitric oxide (NO) production by inhibiting the expression of inducible nitric oxide synthase (iNOS) in THP-1 macrophages. Zingerone also inhibited the expression of TNF-α, IL-1β, and their signal pathway molecules including the toll-like receptor (TLR)/mitogen-activated protein kinase (MAPKase). In particular, zingerone suppressed the expression of absent in melanoma 2 (AIM2) inflammasome components involved in IL-1β production.

4.3 Neurological Mechanisms

The anti-neuroinflammatory mechanisms of zingerone were linked to the inhibition of nuclear factor kappa B (NF-κB) activation and the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome, as well as the reduction in neuronal nitric oxide synthase (nNOS). The anxiolytic and anti-depressive effects of zingerone were also associated with an improvement in cortical cholinergic transmission, the mitigation of oxidative stress, and the upregulation of neurotransmitters such as serotonin and dopamine.

Zingerone has also been shown to act on ion channels in neuronal tissue. With the aid of patch clamp technology, researchers investigated the effects of zingerone on the amplitude, gating, and hysteresis of plasmalemmal ionic currents from both pituitary tumor (GH3) cells and hippocampal (mHippoE-14) neurons. Exposure of the GH3 cells to zingerone differentially diminished the peak and late components of the INa (sodium current).

4.4 Antidiarrheal Mechanisms

Studies have shown that zingerone has the ability to inhibit enterotoxins of various pathotypes of E. coli-induced fluid secretion in the ileum of mice and inhibits colonic motility not only in vitro but also in vivo in rats. A study found that the ginger component zingerone protected cells against C. difficile toxins TcdA and TcdB by blocking either the toxin-binding site on toxin molecules or the host cell receptors (at 0.3 mg/mL). Further investigation of biologically active components showed that zingerone was the active constituent responsible for the anti-diarrhoeal effect of ginger.

5. Scientific Evidence by Area of Use

5.1 Anti-inflammatory Activity

Administration of zingerone significantly attenuated levels of NF-κB, TNF-α, and TGF-β in an adjuvant-induced (Freund's Complete Adjuvant) rheumatoid arthritis rat model. Treatment with FCA resulted in a significant increase in IL-1β, IL-6, and Hs-CRP in the disease control group, and zingerone reduced the levels of IL-1β, IL-6, and Hs-CRP in treated animals. Treatment with zingerone showed a decrease in the thickness of the paw and in the diameter of the joint by interfering with inflammatory mediators, indicating its anti-inflammatory ability in FCA-induced rheumatoid arthritis.

Evidence level: All current inflammation data for zingerone as an isolated compound is from animal (rodent) and in vitro studies. No controlled human clinical trials specifically examining isolated zingerone for inflammatory conditions have been published as of 2025. Evidence is preclinical and mechanistic.

5.2 Antioxidant Activity

In vivo studies show that zingerone can inhibit NF-κB activity and decrease IL-1β levels at 100 mg/kg doses in mice. Zingerone demonstrated protective antioxidant effects against DNA damage in an in vitro study. Both in vivo and in vitro studies on septic mice demonstrate that zingerone administration diminishes reactive oxygen species (ROS) concentration and results in reduced systemic inflammation.

Evidence level: Predominantly in vitro and animal. No human clinical data on zingerone as a direct antioxidant supplement exists in the current literature.

5.3 Antidiabetic and Metabolic Effects

Multiple preclinical studies have examined zingerone in rodent models of diabetes. Results of one study showed that zingerone brought back blood glucose and body weight to normal in diabetes-induced rats. It also improved kidney, liver function, and hyperlipidemia due to diabetes. In histopathological studies, zingerone-treated rats showed improved pancreatic islets of beta cells, normal appearance of liver hepatocytes, portal tracts, and central vein, and improved kidney section of tubules, glomeruli, and blood vessels.

At the molecular level, zingerone protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation, with a probable role of NF-κB activation.

For the broader ginger plant, which delivers zingerone along with other phytochemicals in combination, results of a review of human RCTs revealed that ginger regulated carbohydrate metabolism enzymes in type 2 diabetic subjects. However, these human studies cannot be attributed specifically to zingerone in isolation.

Evidence level: Preclinical (animal models). No published human RCTs specific to isolated zingerone for diabetes exist. Clinical evidence for ginger as a whole preparation in diabetes management is emerging but does not isolate zingerone's contribution.

5.4 Gastroprotective and Antidiarrheal Effects

A controlled animal study published in Medicina (2019) directly examined zingerone for gastroprotection: the study evaluated the effect of zingerone on ethanol-induced gastric ulcers in rats. Gastric ulcers were induced by ethanol (96%, 5 mL/kg, po) in male Wistar rats and zingerone (50, 100, and 200 mg/kg) was administered orally. The findings showed that the mean number and length of gastric ulcers were significantly lower in zingerone-received groups than in the ethanol group (P < 0.05).

For antidiarrheal effects, zingerone (vanillylacetone) is reported to be the active constituent responsible for the antidiarrhoeal efficacy of ginger. Zingerone reduced heat-labile enterotoxin (LT)-induced diarrhoea in ETEC through blocking the binding to host receptors.

Evidence level: Animal model studies only. Well-characterized mechanistic basis in enterotoxin and motility models, but no human clinical trials specifically on isolated zingerone for gastric ulcer or diarrhea have been identified.

5.5 Neuroprotective Effects and Cognitive Function

A systematic review published in 2025 (PMC12249914) specifically addressed zingerone's neuroprotective potential. This study sought to systematically review the effect of zingerone on neuroinflammation and neurobehavioural changes associated with memory and learning impairment and anxiety-like and depressive-like behaviours. A systematic review was conducted using pre-defined search criteria on Google Scholar, Scopus, and Web of Science. Out of 482 studies identified, only 9 studies met the inclusion criteria.

Neuroinflammatory markers such as IL-1β, IL-6, TNF-α, and IBA-1, as well as behavioral parameters including the Morris water maze, Y-Maze, recognition test, passive avoidance test, elevated plus maze, sucrose preference test, and forced swimming test were measured. Zingerone exhibited anti-neuroinflammatory effects by improving IL-1β, IL-6, and TNF-α levels. However, zingerone did not show any significant changes on activated microglia.

The anxiolytic and anti-depressive effects of zingerone were also associated with an improvement in cortical cholinergic transmission, the mitigation of oxidative stress, and the upregulation of neurotransmitters such as serotonin and dopamine. This review provides scientific evidence on the cognitive-enhancing and neuroprotective mechanisms of zingerone, which may be beneficial for future experimental investigations.

Regarding specific neurological ion channel activity, the possibility that zingerone is superior to barbiturates and benzodiazepines for in vivo approaches to anti-epileptic management needs to be further studied in in vivo studies. As an inhibitor of INa and ICa,L, the benefit and toxicity of zingerone need to be carefully investigated.

Evidence level: All neuroprotective evidence is preclinical (rodent behavioral models and in vitro neuronal cell studies). The systematic review identified only 9 qualifying preclinical studies. No human clinical trials are available.

5.6 Radioprotective and Cytoprotective Properties

Zingerone is known as a potent free-radical scavenger with protective properties against reactive oxygen species (ROS)-mediated DNA damage by scavenging and degrading free radicals and ROS. Zingerone treatment to human lymphocytes prior to ionizing radiation (IR) reduced micronuclei, apoptosis, and ROS generation; alkaline comet tail determination also showed decreased comet tail moments.

A preclinical cardioprotective study (PubMed 29736620) investigated zingerone against damage from cancer treatment modalities: the study was designed to assess the potential cardioprotective effects of zingerone against cisplatin or γ-radiation. Zingerone was given by intragastric intubation (25 mg/kg) daily for three successive weeks prior to the induction of cardiotoxicity using a single dose of cisplatin (20 mg/kg, i.p.) or whole body γ-irradiation at a single dose of 6 Gy. Zingerone pre-treatment significantly reduced abnormalities in heart histology and the increase in cardiotoxicity indices, serum lactate dehydrogenase, and creatine kinase-MB activities, as well as plasma cardiac troponin T and B-natriuretic peptide. Furthermore, zingerone ameliorated the state of oxidative stress, as evidenced by a significant decrease in malondialdehyde level and a significant increase in reduced glutathione content and catalase activity. Additionally, zingerone mitigated the increase in inflammatory markers including serum TNF-α, cardiac myeloperoxidase activity, and COX-2 protein expression. Moreover, zingerone alleviated the elevation of caspase-3 gene expression and prominent nuclear DNA fragmentation and attenuated the decrease in mitochondrial complexes' activities.

Reduced reactive oxygen species levels and the avoidance of mitochondrial depolarization show that pretreatment with zingerone significantly reduces the oxidative stress brought on by radiation.

Evidence level: Preclinical (animal models and in vitro human lymphocyte studies). The human lymphocyte data represents ex vivo evidence rather than a clinical intervention trial. No clinical radioprotection trials with isolated zingerone have been conducted.

5.7 Anticancer and Antimutagenic Properties

Ginger contains phenolic and alkanone substances which generally exert strong antioxidative, anti-inflammatory, anticarcinogenic, and antimutagenic activities. Recent studies have shown that zingerone contains anticancer potential. Zingerone (chemically as 4-(4-hydroxy-3-methoxyphenyl)butan-2-one) is an antioxidant, anti-inflammatory, and anticancer phenolic compound that occurs in ginger (Zingiber officinale). The antiproliferative activity of zingerone and its derivatives has been extensively studied by various researchers.

Zingerone has been used therapeutically including as a chemopreventive agent in model experimental colon carcinogenesis in vivo studies on Wistar rats.

Evidence level: In vitro cell-line studies and rodent carcinogenesis models only. No human clinical trial data for zingerone as an anticancer agent exists. This area is in early preclinical stages.

5.8 Hepatoprotective Effects

Released endotoxin-induced inflammation and zingerone as a co-anti-inflammatory therapy significantly reduced the inflammatory response in a mouse model. Improved liver histology and reduced inflammatory markers — MDA, RNI, MPO, tissue damage markers (AST, ALT, ALP) — and inflammatory cytokines (MIP-2, IL-6, and TNF-α) were indicative of the therapeutic potential of zingerone. Zingerone therapy significantly protected liver from endotoxin-induced inflammatory damage by downregulating biochemical as well as molecular markers of inflammation. This study provides evidence that zingerone is a potent anti-inflammatory phytomedicine against hepatic inflammation induced by antibiotic-mediated endotoxemia.

Evidence level: Exclusively preclinical (mouse model). No human hepatoprotection trials with zingerone are currently available.

5.9 Antimicrobial Activity

Zingerone, a less-studied component of ginger, displays antineutrophil potential, which contributes to its role in combating infection-related inflammation. A study found that the ginger component zingerone protected cells against C. difficile toxins TcdA and TcdB by blocking either the toxin-binding site on toxin molecules or the host cell receptors (at 0.3 mg/mL).

Evidence level: Primarily in vitro antimicrobial data. No clinical trials are available for zingerone-specific antimicrobial indications.

5.10 Toxin and Heavy Metal Protection

Zingerone possesses anti-inflammatory, antioxidant, and anti-apoptotic properties and also exhibits protective effects against radiation, chemicals, biological toxins, and oxidative stress. A 2023 animal study examined arsenic-induced lung toxicity: thirty-five male Sprague-Dawley rats were divided into control, SA (sodium arsenite), ZNG, SA+ZNG25, and SA+ZNG50 groups. SA was administered at 10 mg/kg and ZNG was administered at two doses (25 and 50 mg/kg) orally for 14 days. The administration of ZNG reduced oxidative stress by increasing SA-induced decreased antioxidant enzyme activities, increasing Nrf-2, HO-1, and NQO1, and decreasing MDA level. ZNG administration reduced inflammation marker levels. Anti-apoptotic Bcl-2 increased and apoptotic Bax and Caspase-3 decreased with ZNG.

Evidence level: Animal models. No human clinical data available.

6. Body Systems and Health Areas of Association

Based on the published preclinical research, zingerone has been studied across the following physiological systems:

• Gastrointestinal system: Gastroprotection against ulceration; antidiarrheal effects via inhibition of enterotoxins and colonic motility modulation; antispasmodic activity. Zingerone has potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, and antispasmodic properties.
• Immune and inflammatory systems: Suppression of NF-κB, MAPK, and TLR signaling pathways; reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); inhibition of COX-2 and iNOS expression.
• Metabolic system: Preclinical antidiabetic and antilipolytic effects; improvement of lipid profiles and glycemic parameters in rodent models.
• Central nervous system: Preclinical anxiolytic and antidepressant activity; improvement of learning and memory in animal cognitive models; modulation of cholinergic transmission and upregulation of serotonin and dopamine.
• Cardiovascular system: Preclinical cardioprotection against cisplatin- and radiation-induced cardiac damage; antithrombotic properties noted in review literature. Zingerone behaves as an appetite stimulant, anxiolytic, antithrombotic, radiation protective, and antimicrobial.
• Hepatic system: Hepatoprotective activity in endotoxemia and drug-induced liver injury models.
• Respiratory system: Zingerone also supports asthma therapy by decreasing NF-κB and activating protective pathways, as demonstrated in murine asthma models.
• Renal system: Zingerone's reduction of oxidative stress and inflammation is also valuable in damage to kidney tissue caused by arsenic poisoning.

7. Dosage Forms and Reported Dosages in Studies

As zingerone has not been studied in human clinical trials as an isolated supplement, no clinically established human dosage exists. The dosages below are those reported in preclinical studies and should not be construed as recommended human doses.

• Gastroprotection (rat, oral): Zingerone was administered at 50, 100, and 200 mg/kg orally to male Wistar rats in an ethanol-induced gastric ulcer model.
• Cardioprotection (rat, intragastric): Zingerone was given by intragastric intubation at 25 mg/kg daily for three successive weeks prior to the induction of cardiotoxicity.
• Anti-inflammation (mouse, in vivo): Zingerone can inhibit NF-κB activity and decrease IL-1β levels at 100 mg/kg doses in mice.
• Lung protection against arsenite (rat, oral): Sodium arsenite was administered at 10 mg/kg and zingerone was administered at two doses (25 and 50 mg/kg) orally for 14 days.
• Antidiabetic (rat, oral): Studies examining antidiabetic effects in streptozotocin-induced diabetic rats utilized oral dosing, with effects on blood glucose normalization and improvement of organ histopathology observed.

Zingerone is interesting to study because it is readily available and has low acute toxicity, with oral LD₅₀ values of 2580 mg/kg (rat).

8. Safety Considerations and Regulatory Status

8.1 Acute Toxicity

Zingerone has low acute toxicity, with oral LD₅₀ values of 2580 mg/kg (rat). Zingerone is a nontoxic and inexpensive compound. These preclinical toxicity parameters suggest a wide safety margin at doses relevant to dietary exposure, though this has not been formally confirmed in human studies with isolated zingerone.

8.2 GRAS and Regulatory Status

The US FDA has affirmed that Zingiber officinale is generally recognized as safe (GRAS) as a spice, natural seasoning agent, and flavoring agent [21CFR182.10]. Zingerone, as a natural component of ginger, has been evaluated by JECFA and the FEMA Expert Panel. FEMA GRAS categories and use levels are available for zingerone as a flavor ingredient in categories listed by the FEMA Expert Panel.

8.3 Genotoxicity Data Gaps

There are insufficient toxicity data on zingerone (CAS #122-48-5). Hence, in silico evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, physical–chemical properties, and expert judgment, guaiacol (CAS #90-05-1) and 2-methoxy-4-propylphenol (CAS #2785-87-7) were identified as read-across analogs. This indicates that for certain regulatory safety endpoints (e.g., clastogenicity), full empirical data specifically on zingerone itself is not yet available and read-across approaches from structurally related phenols are used.

8.4 Human Clinical Evidence Limitations

Zingerone's pleiotropic activities make it a promising dietary phytochemical with chemopreventive and therapeutic potential, though human clinical evidence is still limited. When ginger is dried and stored, its gingerol rapidly converts to the substances shogaol and zingerone. It remains unknown if any of these substances have medicinal effects in isolation in humans. This is an important caveat: virtually all the pharmacological research on zingerone is preclinical (cell culture or animal models), and no controlled human clinical trials have been conducted using purified zingerone as a supplement or therapeutic agent. Evidence attributed to ginger preparations in human studies cannot be attributed to zingerone specifically.

8.5 Interaction Considerations

An in vivo experiment showing improvement of rat immune function and blood parameters upon administration of zingerone and vitamin C demonstrates synergistic action between the two compounds. This suggests potential for additive or synergistic antioxidant interactions, though implications for human supplementation have not been characterized. Because zingerone shares its parent plant with gingerols and shogaols, and ginger as a whole has been associated with mild antiplatelet effects in human studies, analogous caution is warranted, though no interaction data for isolated zingerone in humans is available in the literature.

9. Summary of Evidence Strength

Across all therapeutic areas investigated, the evidence base for zingerone as an isolated bioactive compound consists almost entirely of in vitro mechanistic studies and animal model experiments. The mechanistic picture is well-developed — particularly regarding NF-κB-mediated anti-inflammatory actions, free-radical scavenging, protection of antioxidant enzyme systems (SOD, CAT, GSH, GPX), and modulation of apoptotic pathways. However, zingerone's pleiotropic activities make it a promising dietary phytochemical with chemopreventive and therapeutic potential, though human clinical evidence is still limited. The gap between robust preclinical data and clinical validation represents the central challenge for zingerone research. Human studies on ginger as a whole plant preparation (relevant to nausea, metabolic effects) cannot be used to draw conclusions about zingerone specifically, as multiple bioactive compounds are present simultaneously and their individual contributions are not isolated in such trials.

References

• Ahmad B et al. A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone). PMC / PubMed PMID 26106644.
• Promising influences of zingerone against natural and chemical toxins: A comprehensive and mechanistic review. PubMed PMID 37562703.
• Zingerone – Wikipedia.
• Zingerone | C11H14O3 | CID 31211 – PubChem (NIH).
• Zingerone – ScienceDirect Topics Overview.
• Ethnopharmacologic investigation of ginger (Zingiber officinale). ScienceDirect / Journal of Ethnopharmacology.
• Clinical aspects and health benefits of ginger (Zingiber officinale) in both Traditional Chinese Medicine and modern industry. Taylor & Francis Online.
• Ginger From Ancient Times to the New Outlook. PMC Article PMC4377061.
• Zingerone Suppresses Liver Inflammation Induced by Antibiotic Mediated Endotoxemia. PMC Article PMC4159778.
• A critical review of Ginger's (Zingiber officinale) antioxidant, anti-inflammatory, and immunomodulatory activities. PMC Article PMC11187345.
• Modulation of age-related NF-kappaB activation by dietary zingerone via MAPK pathway. PubMed PMID 20211236.
• Zingerone modulates adjuvant-induced rheumatoid arthritis by regulating inflammatory cytokines and antioxidants. PMC Article PMC8018447.
• The "root" causes behind the anti-inflammatory actions of ginger compounds in immune cells. PMC Article PMC11239339.
• Zingerone-Induced Autophagy Suppresses IL-1β Production by Increasing the Intracellular Killing of Aggregatibacter actinomycetemcomitans in THP-1 Macrophages. PMC Article PMC10452316.
• Zingerone as a Neuroprotective Agent Against Cognitive Disorders: A Systematic Review of Preclinical Studies. PMC Article PMC12249914.
• Zingerone Modulates Neuronal Voltage-Gated Na+ and L-Type Ca2+ Currents. MDPI International Journal of Molecular Sciences, 2022.
• Cardioprotective effect of zingerone against oxidative stress, inflammation, and apoptosis induced by cisplatin or gamma radiation in rats. PubMed PMID 29736620.
• Protective effects of zingerone derivate on ionizing radiation-induced intestinal injury. PMC Article PMC7357233.
• Pharmacology of natural radioprotectors. Archives of Pharmacal Research, Springer.
• Gastroprotective Effect of Zingerone on Ethanol-Induced Gastric Ulcers in Rats. PMC Article PMC6473471 / Medicina (Kaunas), 2019.
• Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria. PMC Article PMC9967904.
• Protective effects of zingerone against sodium arsenite-induced lung toxicity. PMC Article PMC10440130.
• Ginger (Zingiber officinale) and Zingerone Antioxidant Properties Studied Using Hydrodynamic Voltammetry, Zingerone Crystal Structure and DFT. PMC Article PMC12609149.
• Antidiabetic, Hypolipidemic and Histopathological Analysis of Zingerone in Streptozotocin Induced Diabetic Rats. International Journal of Pharmaceutical Sciences and Research.
• Safety Assessment of Zingiber officinale (Ginger)-Derived Ingredients. Cosmetic Ingredient Review (CIR), 2022.
• ZINGERONE – FEMA Flavor Library. Flavor and Extracts Manufacturers Association.
• RIFM Fragrance Ingredient Safety Assessment, Zingerone, CAS 122-48-5.
• Evidence-Based Human Clinical Trials on Antidiabetic Herbal Remedies Commonly Used in the Middle East. PMC Article PMC12244296, 2025.
• Antidiabetic and Anti-Inflammatory Potential of Zingiberaceae Plants in Dietary Supplement Interventions. PMC Article PMC12844493.